logo
SMCY Is an Income Hack on Supermicro

SMCY Is an Income Hack on Supermicro

Globe and Mail8 hours ago
Key Points
Option-writing and selling covered calls is a low-risk way of cash-monetizing existing positions in individual stocks.
The strategy, however, comes with downsides, like limiting your net-upside potential.
Cash-hungry growth investors looking for new picks for a tax-deferring retirement account may want to consider this ETF despite its relatively high expense ratio.
Are you an income-seeking investor who also wants -- or needs -- growth? That's a bit of a pickle. After all, the more you have of one, the less you typically have of the other.
There are some picks that let you have your proverbial cake and eat it too, however. While they're not a great fit for everyone's portfolio, option-writing-focused exchange-traded funds (ETFs) can provide ongoing dividend income in addition to offering you most of the benefits of owning stocks. There's even a handful of single-stock-focused option-writing ETFs.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
One of these ETFs worth a closer look right now is the YieldMax SMCI Option Income Strategy ETF (NYSEMKT: SMCY), which turns something like a position in Super Micro Computer (NASDAQ: SMCI) into an income-generating holding.
Here's the deal.
What the heck is option writing?
Don't sweat it if you're not familiar with options; plenty of veteran investors aren't. The kinds of stock options that are bought and sold via an exchange just aren't something most people need to bother delving into.
Still, there's nothing wrong with understanding them. You absolutely should understand options if you're going to consider any such income-producing exchange-traded funds -- even if you're never going to directly trade options for yourself.
In the most basic sense, an option is a bet that a particular stock or index will make a particular move within a predetermined period of time. Call options are bullish bets. Put options are bearish bets. Like any other bet, you pay to make these wagers.
Options are also legitimate securities, though, not only trading as such but priced in the familiar bid/ask auction format that allows their price to constantly change. A call option gains in value when the price of the underlying stock or index does, while a put option gains value when the underlying stock or index falls. Conversely, call options lose value when the stock or index in question falls, while put options lose ground when the index or stock at its basis gains in value.
Here's the fun part for income-seeking investors: You don't just have to buy options and then hope to sell them for a profit in the future. You can sell options first, pocket the proceeds, and then aim to cover these trades in the future by buying them back at a lower price. Or, better still, just let those options expire altogether, essentially exiting the trade at no cost.
That's option writing.
There's risk, of course. The chief risk is just that you're forced to buy (or "cover") these option trades at a price above your initial sale price, locking in losses. Or, in the case of the covered call strategy that YieldMax is using with its ETFs, you could be forced to hand over shares of the underlying stock that are essentially serving as collateral for your option trade. In most cases, you'd be doing so while the stock in question is rallying, meaning you're missing out on much of that ticker's upside. This is why option selling can be such a tricky business.
(If you still don't fully understand the idea, it might be worth rereading the section you just completed before proceeding to the next one.)
How the YieldMax SMCI Option Income Strategy ETF works
Enter the YieldMax SMCI Option Income Strategy ETF.
Just as the name implies, the fund managers of the YieldMax SMCI Option Income Strategy ETF regularly sell call options against shares of Super Micro Computer that the fund already holds. This generates ongoing income, most of which is distributed to the fund's owners each and every month. However, in that the fund also owns a bunch of Super Micro Computer shares, holding this fund is somewhat akin to holding a stake in the stock itself. That's why the two investments generally move in the same direction, even if they don't move to the same degree.
It usually works well enough. Although SMCY's net asset value (or market price) has unsurprisingly trailed the performance of SMCI since the fund launched in September of last year, it's also dished out $20.20 worth of per-share dividends -- or distributions -- during this time. That's about twice the ETF's current market price, almost keeping its total net return even with Super Micro Computer shares' performance during this stretch. It just delivered about half of this performance in the form of dividend income instead of capital gains. Indeed, SMCY's trailing-12-month dividend yield stands at just over 100%.
Data by YCharts
Just think it through, keeping the risks and downside in mind
It seems almost too good to be true. You're getting the bulk of the net benefit of owning a great growth stock, but you're getting a big chunk of this benefit in the form of cash. In many ways, it is a great alternative to outright owning a stake in SMCI -- particularly for investors who like to constantly accumulate cash to fund new growth investments.
There are downsides and risks worth considering, though. Chief among these risks is the underlying strategy of selling or writing options itself.
Although the ETF's managers do a great job of balancing the inherent risk and reward of options trading, there are some risks that simply can't be managed away. In this case, the big risk is just that SMCI shares unexpectedly soar, and the fund is forced to hand over shares of Super Micro Computer in the midst of a rally. That, or the fund is forced to cover what are essentially "short" option trades by exiting these positions at a loss. Again, the call options that YieldMax is selling gain in value when SMCI rises, but that works against the strategy at work here. SMCY's managers want the value of the options they've already sold to lose ground.
Sooner or later, it will happen. Even if it only happens occasionally, it can hurt the value of the fund in a hurry.
The other downside is just the cost of managing such a fund.
Unlike enormous index funds like the SPDR S&P 500 ETF Trust or the Vanguard S&P 500 ETF, the YieldMax SMCI Option Income Strategy ETF's annual expense ratio -- or management fee -- is hefty, at nearly 1%. Despite what many fund companies will argue, that does take a direct toll on net performance.
Also, bear in mind that income-generating funds like this one tend to create a pretty big tax liability every year. Distributions are essentially dividends, after all.
Still, there are some scenarios where an exchange-traded fund like this one makes sense for certain investors. Growth investors who would like some of their gains in the form of ongoing income, for instance, may be interested. That's particularly true if the position is going to be held within a tax-deferring retirement account.
The key, of course, is just figuring out whether or not the underlying stock in question is worth owning in the first place. If you don't actually want to buy and hold Super Micro Computer, the income aspect of YieldMax SMCI Option Income Strategy ETF alone doesn't make it more attractive enough to matter. Fellow Fool.com contributor Brett Schafer's got something to say about that.
Should you invest $1,000 in Tidal Trust II - YieldMax Smci Option Income Strategy ETF right now?
Before you buy stock in Tidal Trust II - YieldMax Smci Option Income Strategy ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tidal Trust II - YieldMax Smci Option Income Strategy ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!*
Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 30, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Aircraft Arresting System Market Worth USD 1.84 Billion by 2030 with Growth Driven by Increased Military Airbase Deployments
Aircraft Arresting System Market Worth USD 1.84 Billion by 2030 with Growth Driven by Increased Military Airbase Deployments

Globe and Mail

time27 minutes ago

  • Globe and Mail

Aircraft Arresting System Market Worth USD 1.84 Billion by 2030 with Growth Driven by Increased Military Airbase Deployments

"Aircraft Arresting System Market" Mordor Intelligence has published a new report on the Aircraft Arresting System Market offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction According to a 2025 report on the Aircraft Arresting System Market by Mordor Intelligence, the market is estimated at USD 1.33 billion in 2025 and projected to reach USD 1.84 billion by 2030, growing at a CAGR of 6.67% during the forecast period. The aircraft arresting system market plays a critical role in aviation safety, ensuring rapid deceleration of aircraft during emergency landings or routine operations on military and commercial runways Key Trends in the Aircraft Arresting System Market Increased Military Airbase Deployments Global expansion of military airbases is driving demand for reliable aircraft arresting systems. Countries are investing in new bases and upgrading existing runways to ensure safe operations for advanced fighter aircraft, leading to consistent market growth. Modernization and Retrofitting of Existing Systems Many air forces are retrofitting old arresting systems with modern cable-based systems and advanced net barriers to support newer, heavier aircraft. This trend ensures continued operational readiness without the need for complete infrastructure overhaul. Growth in Naval Aviation Arresting Systems Rising procurement of aircraft carriers by countries like the United States, China, and India is increasing demand for carrier-based arresting systems. These systems are specifically engineered to withstand high-force landings on short carrier decks. Adoption of Engineered Material Arresting Systems (EMAS) in Civil Airports Commercial airports are installing EMAS to prevent runway overruns, aligning with stricter international safety regulations. This is especially prevalent in North America and Europe, enhancing overall airport safety. Focus on Safety Compliance and Performance Standards Aviation safety authorities are implementing stringent guidelines for arresting systems, prompting manufacturers to innovate and upgrade products for higher energy absorption, better durability, and safer deceleration. Market Segmentation By Platform Sea-based Aircraft Arresting Systems Sea-based systems used primarily on aircraft carriers, are designed to halt high-speed landings on short decks at sea. According to the Mordor Intelligence report, this platform is the fastest-growing segment, with an anticipated Compound Annual Growth Rate (CAGR) of through 2030. Land-based Aircraft Arresting Systems Land-based arresting systems, installed at military airports and increasingly at commercial airports, currently hold the majority share of the market. In 2024, this platform captured approximately 64.55% of total market revenue. By Technology Type Cable and Reel Cable and Reel systems remain the largest segment by revenue, holding around of the market in 2024. These are the traditional arresting gear used on military airbases and carriers, where a tailhook on the aircraft catches a cable. Engineered Material Arresting System (EMAS) EMAS is growing rapidly, with a projected CAGR. It consists of crushable materials (like cellular concrete blocks) laid at runway ends to stop overrunning aircraft by absorbing energy as the wheels sink into them. By End User Military Airbase Military airbases represented approximately % of the total aircraft arresting system market in segment includes permanent, expeditionary, and overrun arresting gear such as hook‑cable systems and net barriers deployed at military airfields. These installations are critical for fighter and trainer aircraft operations, particularly during short‑runway landings, aborted take-offs, or emergency situations. The demand reflects ongoing investments in fifth-generation fighter fleets and agile combat employment, where reliable stopping mechanisms are essential for mission readiness. Aircraft Carrier Aircraft carriers constitute the fastest-growing end-user within the market, with a growth rate of % CAGR projected through 2030. Naval aviation demands high-performance arresting gear installed aboard carriers to manage energy absorption in short deck environments under maritime conditions. By Component Energy Absorber Energy absorbers held the largest share among components, accounting for approximately 37.29 % of the market in 2024. These components are vital for dissipating the kinetic energy of landing or aborting aircraft. They include hydraulic cylinders, rotary-friction units, and crushable materials (in EMAS), depending on the system type. Hook and Cable Hook-and-cable assemblies are the core mechanical interface in cable-based arresting systems. This component includes the steel cables stretched across a runway or carrier deck and the aircraft's tailhook assembly. With cable-based systems representing about % of technology-type revenue, hook-and-cable components are essential for reliable aircraft stopping operations As modern carriers and airbases upgrade to support new fighter fleets, demand for durable, high-strength hook-and-cable units continues to rise. By Geography North America North America remains the largest market for aircraft arresting systems, driven by extensive military infrastructure and commercial airport safety initiatives. The region accounted for around 35.07% of market revenue in 2024. Europe Europe holds a significant market share, supported by active airbase upgrades across NATO countries and increasing EMAS installations at busy airports to enhance safety. Countries such as the United Kingdom, France, and Germany are investing in next generation arresting systems to support advanced fighter aircraft. Key Players General Atomics A leading aerospace and defense company specializing in advanced cable-based arresting gear and cutting-edge electromagnetic arresting systems. Their offerings support both military airbases and naval carriers, reflecting their strong presence in high-performance defense applications. Safran SA A major player in aerospace systems, Safran provides a full portfolio of arresting solutions, ranging from hydraulic and rotary‑friction energy absorbers to net barrier systems. They serve both civil airports and military platforms, leveraging their international manufacturing and support networks. Sojitz Aerospace Corporation This company brings expertise in aircraft arresting solutions, particularly in Asia-Pacific markets. They work closely with regional defense and civil aviation authorities to supply and maintain arresting systems, supported by strong logistical capabilities in the region. Conclusion The aircraft arresting system market is poised for steady growth through 2030, supported by a combination of defense modernization programs, increased military airbase deployments, and enhanced runway safety requirements in commercial aviation. Military airbases remain the largest end user due to the constant need for reliable arresting systems to ensure operational readiness and pilot safety during training and combat operations. Industry Related Reports Firefighting Aircraft Market: The Firefighting Aircraft Market report segments the industry by aircraft type (rotorcraft and fixed-wing), maximum take-off weight (below 50,000 kg and above 50,000 kg), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa). It provides market sizes and forecasts for each of these segments in terms of value (USD). Hybrid Aircraft Market: The Hybrid Aircraft Market report segments the market by aircraft type (regional transport aircraft, business jets and light aircraft, and others), mode of operation (piloted and autonomous), lift technology (conventional take-off and landing, and others), propulsion architecture (series hybrid, parallel hybrid, and turbo-electric), and geography (North America, Europe, and others). The market forecasts are presented in terms of value (USD). Aircraft Carrier Ship Market: The Aircraft Carrier Ship Market report segments the industry by type (amphibious assault ship, helicopter carrier, fleet carrier), technology (conventional powered, nuclear powered), configuration (catapult-assisted take-off barrier arrested-recovery (CATOBAR), short take-off but arrested recovery (STOBAR), short take-off but vertical recovery (STOVL)), and geography (North America, Europe, Asia-Pacific, and the rest of the world). About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@

Iovance Biotherapeutics CFO Resignation and Interim Appointment
Iovance Biotherapeutics CFO Resignation and Interim Appointment

Globe and Mail

timean hour ago

  • Globe and Mail

Iovance Biotherapeutics CFO Resignation and Interim Appointment

Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Iovance Biotherapeutics ( (IOVA)) just unveiled an announcement. On June 30, 2025, Iovance Biotherapeutics announced the resignation of Jean-Marc Bellemin as Chief Financial Officer, effective immediately, with Matthew W. Rosinack stepping in as interim Principal Financial Officer and Principal Accounting Officer. Rosinack, who has extensive experience in finance roles at various biotechnology and medical device companies, has been with Iovance since September 2021 and will temporarily fill the role as the company navigates this transition. The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page. Spark's Take on IOVA Stock According to Spark, TipRanks' AI Analyst, IOVA is a Neutral. Iovance Biotherapeutics' stock score reflects its current growth phase marked by significant revenue increases and strong equity, offset by ongoing losses and cash flow challenges. The technical indicators suggest bearish momentum, while mixed earnings call sentiments and recent corporate events add moderate risk. The valuation is impacted by negative earnings, typical for a company investing heavily in growth. To see Spark's full report on IOVA stock, click here. More about Iovance Biotherapeutics Average Trading Volume: 13,697,268 Technical Sentiment Signal: Sell Current Market Cap: $581M See more data about IOVA stock on TipRanks' Stock Analysis page. Disclaimer & Disclosure Report an Issue

Point of Care Diagnostics Market to Hit USD 22.63 Billion by 2029 with 8.5% CAGR
Point of Care Diagnostics Market to Hit USD 22.63 Billion by 2029 with 8.5% CAGR

Globe and Mail

timean hour ago

  • Globe and Mail

Point of Care Diagnostics Market to Hit USD 22.63 Billion by 2029 with 8.5% CAGR

"The major players operating in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK)" Browse 786 market data Tables and 64 Figures spread through 577 Pages and in-depth TOC on "Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029 The global point of care diagnostics market valued at US$ 14.26 billion in 2023, is forecasted to grow at a robust CAGR of 8.5%, reaching US$ 15.05 billion in 2024 and an impressive US$ 22.63 billion by 2029. The growing prevalence of chronic diseases, such as diabetes has necessitated a need for routine monitoring with early and timely detection. Since these conditions need to be constantly monitored, the demand for quick, effective, and appropriate testing methods have expanded. For instance, increasing demand for POC diagnostics like glucose monitoring products is because of the easy, quick results, which patients get, helping them to take care of the disease and make an early intervention. Government initiatives promoting POC testing, including investments in health care innovation are also contributing to increased market growth. Browse in-depth TOC on " Point of Care Diagnostics Market" 778 - Tables 59 - Figures 564 - Pages Advances such as miniaturized, transportable diagnostic devices, which present laboratory-quality findings outside of health care settings, represent a leading technological shift within the point of care diagnostics market. These small devices, largely based on new, advanced forms of biosensors, will deliver testing in real-time with higher degrees of accuracy at a faster cost and are sure to revolutionize health care. These will affect health care primarily in areas related to conditions whose management requires routine monitoring, which includes diabetes and infectious diseases. As these devices continue to become increasingly accessible and affordable, they are going to create new business opportunities in home healthcare, telemedicine, and emergency care, and accelerating adoption across all patient populations. Based on mode of purchase, the point of care diagnostics market is segmented into OTC testing products and prescription-based testing products. The prescription-based testing products segment is expected to be the fastest-growing segment in the market. Stricter regulatory standards, focus on quality, and healthcare providers' recommendation for the test are among the key factors that contribute to the high growth rate of prescription-based testing products. These products need to be subjected to very strict quality and safety measures, which improves the credibility and reliability of these products. Healthcare providers actively engage in using these tests in a way that they produce the best clinical results. With the focus on early detection, prescription-based testing continues to experience strong market growth, which is driving its high growth rate. Categorized by technology, the point of care diagnostics market is segmented into immunoassays, molecular diagnostics, and biochemistry. The biochemistry segment is the dominant technology segment because these tests can quickly, reliably, and cost-effectively provide the results for conditions such as diabetes and pregnancy & fertility testing. Real-time results offered by biochemistry-based tests, like glucose meters are easy to use and well-suited both for homecare and emergency applications. Such technologies assure on-site diagnosis without the complexity of expensive laboratory infrastructure in a point of care environment. With such convenience, accessibility, and ability to cater to increasing demands for rapid and efficient testing, biochemistry technology continues to lead the market. The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), and Boditech Med Inc. (South Korea). The market players have adopted various strategies such as development of advanced products, partnerships, expansions, and acquisitions to strengthen their position in the point of care diagnostics market. The organic and inorganic strategies have helped the market players expand globally by providing advanced point of care tests. Abbott is a key player in the point of care diagnostics market, offering a comprehensive range of diagnostic solutions such as blood screening, immunoassays, and clinical chemistry systems. The company's strong global presence allows it to expand its reach in both established and emerging markets. Abbott stays ahead of the competition through continuous innovation and a focus on research and development. By introducing new products and securing important regulatory approvals, Abbott has solidified its leadership. For example, in April 2024, the company's i-STAT TBI cartridge received FDA clearance to be used with whole blood, further strengthening its position in the POC diagnostics market. F. Hoffmann-La Roche Ltd is a major player in the global point of care diagnostics market, having gained a reputation as a leader in the diagnostics market. Its extensive portfolio and global presence have enabled the company to maintain its competitive edge. Roche has an excellent direct and indirect distribution network across the world, which allows it to compensate for demand volatility in the various markets. Its strategic focus both on organic and inorganic growth strategies further strengthens the company's market presence. For instance, the cobas pulse system was launched by Roche in January 2022 as a connected point-of-care solution to be used with professional blood glucose monitoring only in certain CE Mark countries. All these strategies, along with its strong presence in the market, have given Roche further opportunities to enhance its position within the point of care diagnostics market. Siemens Healthineers AG is a leading company in the point of care diagnostics market, providing a broad range of products like clinical chemistry platforms, immunodiagnostics, and molecular diagnostic testing. The company is committed to expanding its portfolio through strategic acquisitions and innovations in order to respond to the changing needs of patients and healthcare providers. Moreover, Siemens Healthineers focuses on partnerships to further strengthen its position in the market. With a significant worldwide presence in over 70 countries, the group is poised well for growth in the POC diagnostics market. For more information, Inquire Now!

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store